The analgesics market is on track to achieve a revenue of US$ 91.62 billion in 2024. The market share of analgesics is increasing continuously in the drugs and medication sector, which has the ability to translate into a CAGR of 4.6% during the forecast period. This promising growth of the industry is slated to culminate at a valuation of about US$ 143.65 billion by 2034.
| Report Attribute | Details |
|---|---|
| Market Size (2024) | US$ 91.62 billion |
| Market Anticipated Forecast Value (2034) | US$ 143.65 billion |
| Market Projected Growth Rate (2024 to 2034) | 4.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising cases of opioid dependency and the abuse of painkillers have led to the establishment of different abuse-deterrent systems and laws, which are put forward as a deterrent to the market. On the other hand, the forecast period is characterized by remunerative opportunities through technological development in the pharmaceutical industry to manufacture advanced versions of these drugs.
The market was valued at US$ 66.36 billion in 2018. The global market expanded at 5.6% CAGR over the past 5 years between 2018 and 2023. The overall market value was about US$ 87.14 billion by 2023.
| Attributes | Details |
|---|---|
| Market Value (2018) | US$ 66.36 billion |
| Market Revenue (2023) | US$ 87.14 billion |
| Market Historical Growth Rate (CAGR 2018 to 2023) | 5.6% CAGR |
Principal Consultant
Long-term diseases, and cardiovascular disorders, in particular, contribute to industry growth. A rise in the prevalence of diseases such as cancer has also increased the number of people suffering from chronic pain.
Improving healthcare infrastructure is a significant factor influencing the growth rate of the overall market. Further, various government organizations are striving to improve healthcare infrastructure by increasing funding, which will further affect market dynamics.
The introduction of novel drug delivery systems has created more opportunities for market suppliers in the last few years. Further development of novel drug delivery systems and its spread in African and Asian countries has the potential to create and improve the future outlook for opioid analgesics.
Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased sales globally. According to the International Association for the Study of Pain (IASP), around 20-30% of opioids prescribed for chronic pain are being misused. Besides this, as per the association, up to 10% of the total opioid consumers are addicted to them.
Biotechnology is limiting the growth of the market due to the growth of biologics for treating inflammatory and neuropathic pain. Biologics are considered more effective than analgesics, which only provide effective pain relief for 50% of patients, and are therefore seeing greater use.
The table below lists the countries with a sizable market share and high growth opportunities.
| Regional Market Comparison | CAGR (2024 to 2034) |
|---|---|
| United States | 3.2% |
| Germany | 3.4% |
| United Kingdom | 3.1% |
| Thailand | 5.4% |
| India | 6.8% |
Government initiatives to favor the utilization of pain relief drugs exhibit high demand, expected at 3.2% CAGR through the course of the forecast period. The pain relief medication industry is gaining prominence in the United States due to the growing percentage of people susceptible to chronic and lifestyle-related diseases.
As per the documentation in 2016 by the National Health Institute, over 20% of adults in the USA suffer from chronic pain and 8% have high-impact chronic pain. Additionally, the US Food and Drug Administration's (USFDA) approval of a strong pipeline of effective drugs is expected to support market growth.
The rising number of over-the-counter (OTC) pharmacies in the country is anticipated to result in the growth of the regional market at 3.4% CAGR through 2034. The trend of self-medication in Germany is highly prevalent. Sales of non-prescription analgesics via OTC pharmacies in Germany have been characterized as one of the main drivers of the market in the country.
There has been a swift trend favoring analgesic utilization in the United Kingdom that has the potential to translate into a CAGR of 3.1% through 2034. The country is registering higher demand mostly concentrated in the older or geriatric population aiming to achieve a better quality of life.
Commercializing opioid-tolerant drugs is found to be one of the main opportunities for the United Kingdom market players in the opioid drugs sector.
The market in India is projected to expand at a CAGR of 6.8% over the projected years. According to research on analgesic utilization in public hospitals in India, the utilization of NSAIDs and opioids showed a higher trend than other types of analgesics.
For pain management, the governing body of India is encouraging doctors to prescribe non-opioid analgesics, which provides an opportunity for companies to introduce novel non-opioid drugs.
Additionally, key manufacturers are present in the market to manufacture and distribute analgesic drugs, and consumer expenditure on healthcare is increasing, factors positively impacting the market in the country.
Thailand is experiencing a remarkable rise in painkiller consumption resulting in a forecasted CAGR of 5.4% for the market. The introduction of non-opioid analgesics in the country is expected to promote the sales of non-steroidal anti-inflammatory drugs over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attributes | Details |
|---|---|
| Top Pain Indication Segment | Surgical Pain |
| Total Market Share in 2024 to 2034 | 45.6% |
Surgical pain is slotted in to hold a revenue share of 45.6% in 2024. The higher adoption of surgical procedures worldwide is the key reason driving the surgical pain segment. Also, the impact of the NSAIDs market on improving healthcare outcomes has leveraged the use of analgesic painkillers during surgery.
The growing prevalence of diseases requiring surgical treatment, like heart disease, cancer, stroke, and arthritis is poised to further increase the demand for painkillers in this segment.
| Attributes | Details |
|---|---|
| Top Drug Class Segment | Opioids |
| Total Market Share in 2024 | 47.8% |
Based on drug class, opioid is expected to be used for the production of 47.8% of the analgesics in 2024. High demand for opioid drug classes is because of the rising burden of chronic pain and inflammation incidences globally.
The controlled sales of opioid analgesics contribute to a higher market share for hospital pharmacies. Further, private and government funding for pharmaceutical manufacturing segments and Research and Development activities for developing opioid products have boosted the growth of this segment.
Key players are focusing on novel and innovative approaches for the development of non-opioid or non-addictive formulations for pain management. Leading companies are strengthening their product portfolio and global footprint through acquisitions.
The strategy of expansion, new product launches, and approvals by key manufacturers is further strengthening their market presence. Besides these, mergers and acquisitions have emerged as key growth strategies adopted by market players.
Various acquisition strategies and product launches have been employed by new market players to increase their market presence. For example, Advil Dual Action was launched by GlaxoSmithKline PLC on September 10, 2020, and consists of two or more pain-relieving ingredients such as ibuprofen and acetaminophen.
Recent Developments in the Global Analgesics Market
The market is estimated to be around US$ 91.62 billion in 2024.
The market is set to develop at 4.6% CAGR during the forecast period.
The market is predicted to be valued at US$ 143.65 billion by 2034.
Opioids are anticipated to account for nearly 47.8% revenue share of the global market in 2024.
India is predicted to witness a CAGR of 6.8% in sales of analgesics through 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Class, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Class, 2024 to 2034
5.3.1. Opioids
5.3.2. NSAIDs
5.3.3. Local Anaesthetics
5.3.4. Acetaminophen
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034
6.3.1. Surgical Pain
6.3.2. Cancer Pain
6.3.3. Neuropathic Pain
6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Route of Administration, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Route of Administration, 2024 to 2034
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Transdermal
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Store
8.3.4. Clinics
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Indication
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Indication
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Indication
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Indication
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Drug Class
12.2.3. By Indication
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Drug Class
13.2.3. By Indication
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Drug Class
14.2.3. By Indication
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Drug Class
15.2.3. By Indication
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Indication
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2023
17.1.2.1. By Drug Class
17.1.2.2. By Indication
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2023
17.2.2.1. By Drug Class
17.2.2.2. By Indication
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2023
17.3.2.1. By Drug Class
17.3.2.2. By Indication
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2023
17.4.2.1. By Drug Class
17.4.2.2. By Indication
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2023
17.5.2.1. By Drug Class
17.5.2.2. By Indication
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2023
17.6.2.1. By Drug Class
17.6.2.2. By Indication
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2023
17.7.2.1. By Drug Class
17.7.2.2. By Indication
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2023
17.8.2.1. By Drug Class
17.8.2.2. By Indication
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2023
17.9.2.1. By Drug Class
17.9.2.2. By Indication
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2023
17.10.2.1. By Drug Class
17.10.2.2. By Indication
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2023
17.11.2.1. By Drug Class
17.11.2.2. By Indication
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2023
17.12.2.1. By Drug Class
17.12.2.2. By Indication
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2023
17.13.2.1. By Drug Class
17.13.2.2. By Indication
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2023
17.14.2.1. By Drug Class
17.14.2.2. By Indication
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2023
17.15.2.1. By Drug Class
17.15.2.2. By Indication
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2023
17.16.2.1. By Drug Class
17.16.2.2. By Indication
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2023
17.17.2.1. By Drug Class
17.17.2.2. By Indication
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2023
17.18.2.1. By Drug Class
17.18.2.2. By Indication
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2023
17.19.2.1. By Drug Class
17.19.2.2. By Indication
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2023
17.20.2.1. By Drug Class
17.20.2.2. By Indication
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2023
17.21.2.1. By Drug Class
17.21.2.2. By Indication
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2023
17.22.2.1. By Drug Class
17.22.2.2. By Indication
17.22.2.3. By Route of Administration
17.22.2.4. By Distribution Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2023
17.23.2.1. By Drug Class
17.23.2.2. By Indication
17.23.2.3. By Route of Administration
17.23.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Pfizer Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. Sun Pharmaceutical Industries, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Mallinckrodt Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. AbbVie Inc. (Allergan plc)
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. Teva Pharmaceuticals
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Boehringer Ingelheim International GmbH
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. Endo Pharmaceuticals Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
19.1.9. Purdue Pharmaceuticals L.P.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.9.5.2. Product Strategy
19.1.9.5.3. Channel Strategy
19.1.10. Assertio Therapeutics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.10.5.2. Product Strategy
19.1.10.5.3. Channel Strategy
19.1.11. Bayer AG
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.11.5.2. Product Strategy
19.1.11.5.3. Channel Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Analgesics Market
